H mu REL coculture;
slowly metabolized drugs;
low CLint;
clearance prediction;
P450;
activity;
metabolite formation;
CRYOPRESERVED HUMAN HEPATOCYTES;
CIRCULATING DRUG METABOLITES;
BINDING;
PHARMACOKINETICS;
CHALLENGE;
STABILITY;
DISCOVERY;
HEPARG;
CELLS;
D O I:
10.1021/acs.molpharmaceut.6b00396
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Design of slowly metabolized compounds is an important goal in many drug discovery projects. Standard hepatocyte suspension intrinsic clearance (CLint) methods can only provide reliable CLint values above 2.5 mu L/min/million cells. A method that permits extended incubation time with maintained performance and metabolic activity of the in vitro system is warranted to allow in vivo clearance predictions and metabolite identification of slowly metabolized drugs. The aim of this study was to evaluate the static H mu REL coculture of human hepatocytes with stromal cells to be set up in-house as a standard method for in vivo clearance prediction and metabolite identification of slowly metabolized drugs. Fourteen low CLint compounds were incubated for 3 days, and seven intermediate to high CLint compounds and a cocktail of cytochrome P450 (P450) marker substrates were incubated for 3 h. In vivo clearance was predicted for 20 compounds applying the regression line approach, and H mu REL coculture predicted the human intrinsic clearance for 45% of the drugs within 2-fold and 70% of the drugs within 3-fold of the clinical values. CLint values as low as 0.3 mu L/min/million hepatocytes were robustly produced, giving 8-fold improved sensitivity of robust low CLint determination, over the cutoff in hepatocyte suspension CLint methods. The CLint values of intermediate to high CLint compounds were at similar levels both in H mu REL coculture and in freshly thawed hepatocytes. In the H mu REL coculture formation rates for five P450-isoform marker reactions, paracetamol (CYP1A2), 1-OH-bupropion (CYP2B6), 4-OH-diclofenac (CYP2C9), and 1-OH-midazolam (3A4) were within the range of literature values for freshly thawed hepatocytes, whereas 1-OH-bufuralol (CYP2D6) formation rate was lower. Further, both phase I and phase II metabolites were detected and an increased number of metabolites were observed in the H mu REL coculture compared to hepatocyte suspension. In conclusion, H mu REL coculture can be applied to accurately estimate intrinsic clearance of slowly metabolized drugs and is now utilized as a standard method for in vivo clearance prediction of such compounds in-house.
机构:
Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
Healthcare Business Merck KGaA, Dept Drug Metab & Pharmacokinet DMPK, Darmstadt, Germany
F Hoffman La Roche AG, Pharmaceut Res & Early Dev, Basel, SwitzerlandKarolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
Preiss, Lena C.
Georgi, Katrin
论文数: 0引用数: 0
h-index: 0
机构:
Healthcare Business Merck KGaA, Dept Drug Metab & Pharmacokinet DMPK, Darmstadt, Germany
Bayer Healthcare, Dept Drug Metab & Pharmacokinet DMPK, Wuppertal, GermanyKarolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
Georgi, Katrin
Lauschke, Volker M.
论文数: 0引用数: 0
h-index: 0
机构:
Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
Univ Tubingen, Tubingen, GermanyKarolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
Lauschke, Volker M.
Petersson, Carl
论文数: 0引用数: 0
h-index: 0
机构:
Healthcare Business Merck KGaA, Dept Drug Metab & Pharmacokinet DMPK, Darmstadt, Germany
Merck Healthcare KGaA, NCE DMPK, Discovery & Dev Technol, Frankfurter Str 250,Postcode D50-902, D-64293 Darmstadt, GermanyKarolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany
Yamagata, Tetsuo
Zanelli, Ugo
论文数: 0引用数: 0
h-index: 0
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Darmstadt, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany
Zanelli, Ugo
Gallemann, Dieter
论文数: 0引用数: 0
h-index: 0
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany
Gallemann, Dieter
Perrin, Dominique
论文数: 0引用数: 0
h-index: 0
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Darmstadt, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany
Perrin, Dominique
Dolgos, Hugues
论文数: 0引用数: 0
h-index: 0
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Darmstadt, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany
Dolgos, Hugues
Petersson, Carl
论文数: 0引用数: 0
h-index: 0
机构:
Merck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Darmstadt, GermanyMerck KGaA, Global Early Dev Quantitat Pharmacol & Drug Dispo, Grafing, Germany